Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119350 | 0.83 | CYP1A2 (0.34) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL22652562 | 0.83 | CYP1A2 (0.33) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL23383369 | 0.81 | NPC1 (0.30) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL18687138 | 0.80 | CYP1A2 (0.39) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL22023787 | 0.77 | CNR2 (0.40) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL15979333 | 0.76 | CYP1A2 (0.33) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL29899196 | 0.73 | — | — | |
| SCHEMBL24850747 | 0.73 | — | — | |
| SCHEMBL19388345 | 0.71 | CYP1A2 (0.36) | CYP1A2CYP19A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL19286647 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283129-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283129-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | GFPT1, MPST, XPNPEP1 | CYP1A2 1036/4885CYP19A1 1966/4885CYP2C9 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.